Qureight’s AI 3D Imaging Platform to Support Calluna Pharma’s Phase 2 AURORA Study of CAL101 in Idiopathic Pulmonary Fibrosis (IPF)
- Qureight’s advanced AI 3D imaging platform to be used across clinical trial to evaluate anatomical lung changes in adult patients, including during patient enrolment
- CAL101 is a first-in-class monoclonal antibody that neutralises the S100A4 protein, which is an upstream driver and amplifier of the multiple pro-fibrotic pathways active in IPF

